院外心脏骤停后血小板功能障碍:POHCAR前瞻性观察性队列研究结果
该前瞻性观察性可行性研究在英國一家心脏中心纳入30例可能心源性OHCA患者和30例接受PCI的STEMI患者,急诊入院时即刻采血行床旁血栓弹力测定和血小板功能分析。OHCA组凝血酶受体激活后血小板聚集(TRAP AUC)低于STEMI组:79.3(95%CI 63.7-94.9)vs 101.6(95%CI 87.4-115.8),p=0.03;最大血凝块强度时间延长:1718s(1545s-1906s)vs 1544s(1387s-1709s),p=0.01。两组其他凝血形成与强度指标相当,高纤溶(最大溶解≥15%)常见(STEMI 57%;OHCA 50%)但未增加30天出血风险。作者指出这项小型可行性研究不能得出临床结论,但将为未来研究的样本量计算提供依据。
要点
- OHCA患者入院时凝血酶受体刺激后血小板活化降低:TRAP AUC 79.3(95%CI 63.7-94.9)vs STEMI 101.6(95%CI 87.4-115.8),p=0.03。
- OHCA组最大血凝块强度时间较STEMI组延长:1718s(1545s-1906s)vs 1544s(1387s-1709s),p=0.01。
- 两组其他凝血形成与强度指标相当,提示本队列OHCA后无严重凝血病。
- 高纤溶(最大溶解≥15%)在两组均常见:STEMI 57%、OHCA 50%,但未增加30天出血风险。
- 作者指出这项小型可行性研究不能得出临床结论,但将为未来研究的样本量计算提供依据。
适用人群与场景
- 可能心源性院外心脏骤停(OHCA)后入住英国一家心脏中心的患者,急诊科入院时即刻采血。
- 对照为因ST段抬高型心肌梗死(STEMI)接受经皮冠状动脉介入治疗(PCI)的患者。
诊断标准与关键阈值
- 高纤溶定义为最大溶解≥15%。
研究设计与关键结果
- 前瞻性观察性可行性研究,OHCA组与STEMI组各纳入30例。
- 凝血酶受体刺激后血小板活化(TRAP AUC)OHCA组低于STEMI组:79.3(95%CI 63.7-94.9)vs 101.6(95%CI 87.4-115.8),p=0.03。
- 最大血凝块强度时间OHCA组较STEMI组延长:1718s(1545s-1906s)vs 1544s(1387s-1709s),p=0.01。
- 其他凝血形成与强度指标两组相当。
- 高纤溶(最大溶解≥15%)STEMI组57%、OHCA组50%,未增加30天出血风险。
证据类型、等级与局限
- 证据类型:前瞻性观察性可行性研究。
- 局限:作者指出这项小型可行性研究不能得出临床结论,但将为未来研究的样本量计算提供依据。
对床旁实践的改变
- 作者指出这项小型可行性研究不能得出临床结论,但将为未来研究的样本量计算提供依据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: Coagulation and platelet function following out of hospital cardiac arrest (OHCA) at admission to a UK cardiology centre were investigated prospectively in this observational feasibility study, and compared to that of patients receiving percutaneous coronary intervention (PCI) for ST segment elevation myocardial infarction (STEMI).
METHOD: Blood samples taken immediately at emergency department admission from patients after OHCA of probable cardiac origin were analysed using near-patient thromboelastometry and a platelet function analyser. Physiological parameters, demographic information, bleeding rates and 30-day survival were recorded, and compared to that of patients undergoing PCI for STEMI.
RESULTS: Thirty patients were enrolled into each group. Platelet activation with thrombin receptor stimulation was reduced in OHCA patients compared to STEMI patients; mean TRAP AUC OHCA 79.3 (95% CI 63.7-94.9) vs STEMI 101.6 (95% CI 87.4-115.8), p = 0.03. The maximum clot firmness time was prolonged in the OHCA group compared to the STEMI group; 1718s (1545s-1906s) vs 1544s (1387s-1709s), p = 0.01. Other measures of clot formation and strength were comparable between groups. Hyperfibrinolysis (maximum lysis > = 15%) was common in both groups (57% in STEMI; 50% in OHCA) but did not increase 30-day bleeding risk.
CONCLUSION: OHCA patients demonstrated reduced thrombin receptor function at hospital admission but overall clot formation dynamics comparable to STEMI patients, indicating no gross coagulopathy post OHCA in our cohort. Hyperfibrinolysis was common both post OHCA and after STEMI. The results of this small feasibility study cannot draw clinical conclusions but will inform power calculations for future studies.
参考来源
- Skorko A, Mumford A, Thomas M, et al. Platelet dysfunction after Out of Hospital Cardiac Arrest. Results from POHCAR: A prospective observational, cohort study. Resuscitation. 2019. PMID: 30716426. doi:10.1016/j.resuscitation.2019.01.025
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。